IL-25 inhibits atherosclerosis development in apolipoprotein e deficient mice

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Mantani, Polyxeni T ^a   Dunér, Pontus ^a   Bengtsson, Eva ^a   Alm, Ragnar ^a   Ljungcrantz, Irena ^a   Söderberg, Ingrid ^a   Sundius, Lena ^a   To, Fong ^a   Nilsson, Jan ^a   Björkbacka, Harry ^a   Fredrikson, Gunilla Nordin ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 25; INTERLEUKIN 5; PHOSPHORYLCHOLINE; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 25; UNCLASSIFIED DRUG; ANTI-IGM; ANTIIDIOTYPIC ANTIBODY; APOLIPOPROTEIN E; INTERLEUKIN 17;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG INHIBITION; HYPERLIPOPROTEINEMIA TYPE 3; INNATE LYMPHOID TYPE 2 CELL; LYMPHOCYTE SUBPOPULATION; LYMPHOID CELL; MOUSE; NONHUMAN; OSMOTIC PUMP; ANIMAL; AORTIC DISEASES; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; LYMPHOCYTE; PATHOLOGY; SPLEEN; T LYMPHOCYTE;

MUS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNITY, INNATE; INTERLEUKIN-17; INTERLEUKIN-5; LYMPHOCYTES; MICE; MICE, KNOCKOUT; SPLEEN; T-LYMPHOCYTES;

EID: 84922121986     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117255     Document Type: Article

References (35)

1. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, et al. (2001) IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15: 985-995. PMID: 11754819
2. Owyang AM, Zaph C, Wilson EH, Guild KJ, McClanahan T, et al. (2006) Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med 203: 843-849. PMID: 16606667
3. Kleinschek MA, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, et al. (2007) IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 204: 161-170. PMID: 17200411
4. Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, et al. (2009) Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 58: 1302-1311. doi: 10.2337/db08-1113 PMID: 19289457
5. Barlow JL, McKenzie AN (2011) Nuocytes: expanding the innate cell repertoire in type-2 immunity. J Leukoc Biol 90: 867-874. doi: 10.1189/jlb.0311160 PMID: 21712394
6. Walker JA, Barlow JL, McKenzie AN (2013) Innate lymphoid cells-how did we miss them? Nat Rev Immunol 13: 75-87. doi: 10.1038/nri3349 PMID: 23292121
7. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, et al. (2010) Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A 107: 11489-11494. doi: 10.1073/ pnas.1003988107 PMID: 20534524
8. Neill DR, Wong SH, Bellosi A, Flynn RJ, DalyM, et al. (2010) Nuocytes represent a new innate effector leukocyte thatmediates type-2 immunity. Nature 464: 1367-1370. doi: 10.1038/nature08900 PMID: 20200518
9. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, et al. (2010) Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 463: 540-544. doi: 10.1038/ nature08636 PMID: 20023630
10. Molofsky AB, Nussbaum JC, Liang HE, Van Dyken SJ, Cheng LE, et al. (2013) Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med 210: 535-549. doi: 10.1084/jem.20121964 PMID: 23420878
11. Perry HM, Oldham SN, Fahl SP, Que X, Gonen A, et al. (2013) Helix-Loop-Helix Factor Inhibitor of Differentiation 3 Regulates Interleukin-5 Expression and B-1a B-Cell Proliferation. Arterioscler Thromb Vasc Biol 33: 2771-2779. doi: 10.1161/ATVBAHA.113.302571 PMID: 24115031
12. Baumgarth N (2011) The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 11: 34-46. doi: 10.1038/nri2901 PMID: 21151033
13. Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, et al. (2009) Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 119: 1335-1349. doi: 10.1172/JCI36800 PMID: 19363291
14. Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, et al. (2011) B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res 109: 830-840. doi: 10.1161/CIRCRESAHA.111.248542 PMID: 21868694
15. Kyaw T, Tipping P, Bobik A, Toh BH (2012) Protective role of natural IgM-producing B1a cells in atherosclerosis. Trends Cardiovasc Med 22: 48-53. doi: 10.1016/j.tcm.2012.06.011 PMID: 22841841
16. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12: 204-212. doi: 10.1038/ni.2001 PMID: 21321594
17. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL (2013) Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest 123: 27-36. doi: 10.1172/JCI63108 PMID: 23281407
18. Palinski W, Miller E, Witztum JL (1995) Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 92: 821-825. PMID: 7846059
19. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, et al. (1996) Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16: 1074-1079. PMID: 8696949
20. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, et al. (2005) T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A 102: 1596-1601. PMID: 15665085
21. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, et al. (2003) Influence of interferongamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 23: 454-460. PMID: 12615659
22. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, et al. (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12: 178-180. PMID: 16462800
23. Mallat Z, Ait-Oufella H, Tedgui A (2007) Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc Med 17: 113-118. PMID: 17482092
24. Kleemann R, Zadelaar S, Kooistra T (2008) Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 79: 360-376. doi: 10.1093/cvr/cvn120 PMID: 18487233
25. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, et al. (2004) IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 114: 427-437. PMID: 15286809
26. Miller AM, Xu D, Asquith DL, Denby L, Li Y, et al. (2008) IL-33 reduces the development of atherosclerosis. J Exp Med 205: 339-346. doi: 10.1084/jem.20071868 PMID: 18268038
27. Gronlund H, Hallmans G, Jansson JH, Boman K, Wikstrom M, et al. (2009) Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil 16: 382-386. doi: 10.1097/HJR. 0b013e32832a05df PMID: 19369878
28. Nussbaum JC, Van Dyken SJ, vonMoltke J, Cheng LE,Mohapatra A, et al. (2013) Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 502: 245-248. doi: 10.1038/nature12526 PMID: 24037376
29. Monteleone G, Pallone F, Macdonald TT (2010) Interleukin-25: a two-edged sword in the control of im-mune-inflammatory responses. Cytokine Growth Factor Rev 21: 471-475. doi: 10.1016/j.cytogfr.2010. 05.001 PMID: 20605735
30. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, et al. (2007) Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 50: 540-546. PMID: 17678738
31. Sampi M, Ukkola O, Paivansalo M, Kesaniemi YA, Binder CJ, et al. (2008) Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis. J Am Coll Cardiol 52: 1370-1378. doi: 10.1016/j.jacc.2008.06.047 PMID: 18940525
32. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, Idu MM, et al. (2010) Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 220: 499-508. doi: 10.1002/path.2667 PMID: 20020510
33. Daugherty A (2002) Mouse models of atherosclerosis. Am J Med Sci 323: 3-10. PMID: 11814139
34. Lajoie-Kadoch S, Joubert P, Letuve S, Halayko AJ, Martin JG, et al. (2006) TNF-alpha and IFN-gamma inversely modulate expression of the IL-17E receptor in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 290: L1238-1246. PMID: 16428271
35. Foks AC, van Puijvelde GH, Bot I, Ter Borg MN, Habets KL, et al. (2013) Interruption of the OX40-OX40 Ligand Pathway in LDL Receptor-Deficient Mice Causes Regression of Atherosclerosis. J Immunol 191: 4573-4580. doi: 10.4049/jimmunol.1200708 PMID: 24068673